FIGURE 4.

The effects of PD‐L1 inhibitor durvalumab and VEGFR2 inhibitor apatinib alone or in combination on tube formation, cell migration, and invasion. (A) The effects of these treatments on tube formation. HUVECs were treated with 4 μmol/L durvalumab and 20 μmol/L apatinib (S5248) alone or in combination for 6 h. (B) The cell migration tested by transwell assay. OVCA433 and HeyA8 cells were treated with 4 μmol/L durvalumab and 20 μmol/L apatinib alone or in combination for 48 h. (C) The cell invasion tested by transwell assay. OVCA433 and HeyA8 cells were treated with the same method as above. *P < 0.05; **P < 0.01. Abbreviations: PD‐L1: programmed cell death‐ligand 1; VEGFR2: vascular endothelial growth factor receptor 2; HUVEC: human umbilical vein endothelial cell